Pharmacokinetics of Ginsenoside Rh2, the Major Anticancer Ingredient of Ginsenoside H Dripping Pills, in Healthy Subjects
Authors:
- 5 October 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 10 (6) , 669-674
Abstract
Ginsenoside H dripping pill (GH) is a novel clinical‐stage adjuvant for the treatment of non‐small cell lung cancer. In this study, the pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of GH, was investigated in healthy volunteers. Enrolled volunteers were assigned to 3 cohorts—7.8, 15.6, and 31.2 mg—and received single and/or multiple GH orally. Blood samples were assayed by a validated bioanalytical method, and drug concentrations were analyzed using a noncompartmental methodology. The results showed that ginsenoside Rh2 was absorbed with medium speed and reached Cmax a median of 3 hours after administration. The exposure of ginsenoside Rh2 was approximately dose‐dependent in terms of AUC and Cmax. The plasma concentration of ginsenoside Rh2 reached steady state after oral administration of GH twice daily for 5 days. There was no obvious accumulation in exposure parameters in the multiple‐dose study.Keywords
This publication has 18 references indexed in Scilit:
- Recommendations on the Clinical Use of Compound Danshen Dripping PillsChinese Medical Journal, 2017
- Preliminary study on fabrication, characterization and synergistic anti-lung cancer effects of self-assembled micelles of covalently conjugated celastrol–polyethylene glycol–ginsenoside Rh2Drug Delivery, 2017
- Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in MicePlanta Medica, 2016
- Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagyScientific Reports, 2016
- Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular CarcinomaCell Biochemistry and Biophysics, 2015
- Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cellsOncology Reports, 2012
- Stereoselective Regulations of P-Glycoprotein by Ginsenoside Rh2 Epimers and the Potential Mechanisms From the View of PharmacokineticsPLOS ONE, 2012
- Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128Acta Pharmacologica Sinica, 2011
- Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cellsFitoterapia, 2010
- Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogsFood and Chemical Toxicology, 2009